Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults

NCT00868218 | Completed Phase 1 Results

• 2 other identifiers: PANFLUVAC-2008, Version 2EU PANFLUVAC 44115
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated locally and systemically and by using haematological, biochemical and immunological screening tests. The immunogenicity of the H5N1 vaccine will be assessed through the induction of local and systemic antibody and cellular immune responses. In a pandemic situation, an important aspect is the rapidity of the immune response to the H5N1 vaccine so the detailed kinetics of the immune response will be investigated. The capacity of the vaccine to elicit long lasting immunity and cross reactive immunity to H5 viruses will also be evaluated. Furthermore, the quality of the immune response induced by the vaccine will be studied. The vaccine will be administered as twice the normal human dose (30μg HA) with and without adjuvant, and in a dose sparing manor of half (7.5μg HA) and one tenth (1.5μg HA) of the normal human dose with adjuvant. Sixty subjects will receive two doses of virosomal H5N1 influenza vaccine (separated by 21 ± 4 days) by intramuscular injection into the deltoid muscle. Escalating doses will be separated by a period of one week. Four groups each containing 15 subjects will receive two doses of the pandemic virosomal A/H5N1 influenza vaccine containing: Group 1 30µg HA IM, Group 2 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 3 7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 4 30µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM.

Conditions

Influenza; Healthy

Keywords

Influenza A; pandemic; vaccine; immunogenicity; Virus; H5N1

Outcome Measures

Primary Outcomes (2)

• Solicted Adverse Events

  The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant.

  three months

• Adverse Events

  42 days

Secondary Outcomes (1)

• Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine

  one year

Study Arms (4)

1

ACTIVE COMPARATOR

30µg HA vaccine Intramuscularly administered

Biological: Influenza vaccine

2

ACTIVE COMPARATOR

1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered

Biological: Influenza vaccine

3

ACTIVE COMPARATOR

7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered

Biological: Influenza vaccine

4

ACTIVE COMPARATOR

30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered

Biological: Influenza vaccine

Interventions

Influenza vaccine BIOLOGICAL

Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14

1; 2; 3; 4

Eligibility Criteria

• Age: 19 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy volunteers (as concluded from the medical history, physical examination, and clinical judgment) aged 19 to 50 years old
• Females using a reliable method of contraception (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy test will be required before administration of each dose of vaccine
• Signed informed consent
• Subjects able to understand and comply with the study protocol and complete the Adverse Event Form
• Subjects able to attend the scheduled visits
• Subjects with normal pre-screening values. If a subjects prescreening samples lie outside the reference values he/she will only be included in the study based upon the medical evaluation of the clinical investigator

You may not qualify if:

• Persons with a history of anaphylaxis or serious reactions to any vaccine
• Persons with known hypersensitivity to any of the vaccine components
• Persons who have had a temperature \>38oC during the previous 72 hours
• Persons who have had an acute respiratory infection during the last 7 days
• Women who are pregnant or breast-feeding
• Persons with chronic illness at any stage that could interfere with trial conduct or compliance
• Persons who have received blood products or immunoglobulins parenterally during the previous 3 months
• Persons who have been vaccinated with any vaccine during the 4 weeks preceding the first trial vaccination
• Persons with known or suspected immunosuppressive disease or who use systemic immunosuppressive drugs
• Persons taking immunostimulant therapy
• Persons involved in another clinical trial during the last month.
• Suspected non-compliance

Sponsors & Collaborators

• Rebecca Cox: lead
• Haukeland University Hospital: collaborator
• European Commission: collaborator

Study Sites (1)

Haukeland Univeristy Hospital

Bergen, N-5021, Norway

Location

Related Publications (6)

• Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis. 2012 Jul 15;206(2):158-66. doi: 10.1093/infdis/jis330. Epub 2012 May 2.

  PMID: 22551811 RESULT

• Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nostbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine. 2011 Oct 19;29(45):8049-59. doi: 10.1016/j.vaccine.2011.08.042. Epub 2011 Aug 22.

  PMID: 21864624 RESULT

• Pedersen GK, Sjursen H, Nostbakken JK, Jul-Larsen A, Hoschler K, Cox RJ. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother. 2014;10(8):2408-16. doi: 10.4161/hv.29583.

  PMID: 25424948 RESULT

• Pedersen GK, Hoschler K, Oie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nostbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014 Jul 31;32(35):4550-4557. doi: 10.1016/j.vaccine.2014.06.009. Epub 2014 Jun 18.

  PMID: 24950357 RESULT

• Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets. PLoS One. 2015 Jul 6;10(7):e0131652. doi: 10.1371/journal.pone.0131652. eCollection 2015.

  PMID: 26147369 RESULT

• Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.

  PMID: 25210189 RESULT

MeSH Terms

Conditions

Influenza, Human; Virus Diseases

Interventions

Influenza Vaccines

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Viral Vaccines; Vaccines; Biological Products; Complex Mixtures

Results Point of Contact

• Title: Professor Rebecca Jane Cox
• Organization: University of Bergen

rebecca.cox@uib.no

+4755974668

Study Officials

• Haakon Sjursen, MD

  Haukeland Univeristy Hospital

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 23, 2009
• First Posted: March 24, 2009
• Study Start: March 1, 2009
• Primary Completion: July 1, 2010
• Study Completion: November 1, 2013
• Last Updated: November 18, 2019
• Results First Posted: December 13, 2016

Record last verified: 2019-11

Locations

NO (1)